Well the results show a combination treatment, so no silver bullet. The expense of Remestemcel vs dexamethasone? could be a deciding factor.
"dexamethasone ($3.13 per 4 mg, corresponding to $31 per patient course)" SOC in SA for SARs Cov2
How much of the claimed 75% reduced mortality can be attributed to Remstemcel ? Seems inconclusive so I will leave it to NVT to decide.
Anyway back to 2 bucks maybe.
Ann: COVID ARDS Trial Topline 60-Day Results, page-70
-
- There are more pages in this discussion • 1,559 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |